MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Acquires $39,919.95 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ngar Yee Louie bought 19,665 shares of the firm’s stock in a transaction on Thursday, April 25th. The stock was acquired at an average cost of $2.03 per share, with a total value of $39,919.95. Following the completion of the purchase, the director now owns 1,167,189 shares of the company’s stock, valued at approximately $2,369,393.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

MAIA Biotechnology Trading Up 9.7 %

NYSEAMERICAN:MAIA traded up $0.26 on Friday, reaching $2.94. The company’s stock had a trading volume of 437,552 shares, compared to its average volume of 385,844. MAIA Biotechnology, Inc. has a 1-year low of $0.82 and a 1-year high of $3.07. The stock has a market cap of $60.51 million, a price-to-earnings ratio of -1.96 and a beta of 0.42.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). Sell-side analysts forecast that MAIA Biotechnology, Inc. will post -1.25 earnings per share for the current year.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.